Final 5-Year Follow-Up Results Evaluating Neoadjuvant Talimogene Laherparepvec Plus Surgery in Advanced Melanoma: A Randomized Clinical Trial

Reinhard Dummer; David E Gyorki; John R Hyngstrom; Meng Ning; Tatiana Lawrence; Merrick I Ross

doi:10.1001/jamaoncol.2023.2789

Final 5-Year Follow-Up Results Evaluating Neoadjuvant Talimogene Laherparepvec Plus Surgery in Advanced Melanoma: A Randomized Clinical Trial

JAMA Oncol. 2023 Oct 1;9(10):1457-1459. doi: 10.1001/jamaoncol.2023.2789.

Authors

Reinhard Dummer¹, David E Gyorki^{2

3}, John R Hyngstrom⁴, Meng Ning⁵, Tatiana Lawrence⁶, Merrick I Ross⁷

Affiliations

¹ University Hospital of Zurich, Zurich, Switzerland.
² Olivia Newton-John Cancer Centre, Austin Health, Melbourne, Australia.
³ Now with Peter MacCallum Cancer Centre, Melbourne, Australia.
⁴ University of Utah Huntsman Cancer Institute, Salt Lake City, Utah.
⁵ Parexel, Guangzhou, Guangdong, China.
⁶ Amgen Inc, Thousand Oaks, California.
⁷ The University of Texas MD Anderson Cancer Center, Houston, Texas.

PMID: 37561473
PMCID: PMC10416083 (available on 2024-08-10)
DOI: 10.1001/jamaoncol.2023.2789

No abstract available

Plain language summary

This randomized clinical trial presents the final 5-year follow-up results of neoadjuvant talimogene laherparepvec (T-VEC) plus surgery in patients with advanced melanoma.